Merck KGaA to ask EU agency to reconsider MS oral drug
Merck KGaA to ask EU agency to reconsider MS oral drug
German drugmaker Merck KGaA plans to ask a European watchdog to review a negative opinion issued on multiple sclerosis drug cladribine last month that said the drug's risks outweighed its benefits.
"Merck is committed to the potential of cladribine tablets to meet an unmet medical need as an oral, short-course, disease-modifying drug for multiple sclerosis," the group said in a statement on Monday.
The drug was dealt a major blow in September when the Committee for Medicinal Products for Human Use (CHMP), whose view is invariably adopted by the European Commission for approval of decisions, found that the drug may not be fit for approval. [ID:nLDE68N04J]... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 1 Replies
- 1142 Views
-
Last post by Petr75
-
- 0 Replies
- 112 Views
-
Last post by NHE
-
- 0 Replies
- 1671 Views
-
Last post by NHE
-
- 0 Replies
- 526 Views
-
Last post by NHE
-
- 1 Replies
- 3167 Views
-
Last post by Tif
-
- 0 Replies
- 150 Views
-
Last post by DIM
-
- 2 Replies
- 1091 Views
-
Last post by DIM
-
- 1 Replies
- 2001 Views
-
Last post by raceya